As we begin to reopen Rush University Medical Center for elective procedures and in-person care, we are putting your safety first. For information about COVID-19, see the latest updates. Rush accepts donations to support our response effort, staff, and patients and families.
Treatment Study for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair
This randomized phase III trial studies combination chemotherapy and atezolizumab to see how well it works compared with combination chemotherapy alone in treating patients with stage III colon cancer and deficient deoxyribonucleic acid (DNA) mismatch repair. Drugs used in combination chemotherapy, such as oxaliplatin, leucovorin calcium, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as atezolizumab, may interfere with the ability of tumor cells to grow and spread. Giving combination chemotherapy with atezolizumab may work better than combination chemotherapy alone in treating patients with colon cancer.
In order to participate you must meet the following criteria:
- Have stage III colon adenocarcinoma.
- Have presence of deficient (d) DNA mismatch repair.
You will be excluded from the study if any of the following criteria apply to you:
- Have had a prior therapy, except for one cycle of mFOLFOX6.
- Have a tumor outside the colon, such as extending to the rectum.
This is a partial list of inclusion and exclusion criteria.